Clinical obesity in Asian people: bridging the gap between adiposity and disease
April 27, 2026 / Clinical obesity / Metabolic risk / Asian populations / Visceral fat / Precision medicine
Proposed shift from BMI-based to function-based obesity diagnosis in Asian populations emphasizes visceral fat, metabolic dysfunction, and organ impairment, enabling earlier detection and more precise management of cardiometabolic risk.
Yoga to help manage obesity-related heart and metabolic risks
April 27, 2026 / Obesity management / Cardiometabolic health / Yoga therapy / Insulin resistance / Lifestyle intervention
Yoga shows modest improvements in cardiometabolic health, including blood pressure, lipid profiles, and insulin resistance in overweight individuals, supporting its role as a low-intensity adjunct therapy for managing obesity-related metabolic risk.
As heart, kidney and metabolic health worsen, cancer risk may rise
April 27, 2026 / Cardiometabolic health / Cancer risk / Chronic disease / CKM syndrome / Preventive health
Advanced cardiovascular-kidney-metabolic syndrome is associated with significantly increased cancer risk, highlighting interconnected disease pathways and the importance of integrated prevention strategies targeting cardiometabolic health.
A Simple Sugar in Ultra-Processed Foods May Drive Obesity, Metabolic Disease
April 25, 2026 / Metabolic disease / Fructose metabolism / Obesity risk / Ultra-processed foods / Insulin resistance
Excess fructose, particularly from ultra-processed foods, drives metabolic dysfunction by promoting fat synthesis, insulin resistance, and liver disease, highlighting its role in obesity and cardiometabolic risk beyond caloric contribution.
Common sweetener may trigger fat buildup in ways experts didn’t expect
April 23, 2026 / Fructose metabolism / Metabolic syndrome / Obesity risk / Insulin resistance / Processed sugars
Fructose uniquely promotes fat synthesis, insulin resistance, and metabolic dysfunction by altering liver metabolism, suggesting its role in obesity and cardiometabolic disease extends beyond calorie intake, particularly with high consumption from processed foods.
A Swedesboro family turned to weight-loss surgery for their 15-year-old son. As childhood obesity rises, it can be a viable option
April 24, 2026 / Childhood obesity / Bariatric surgery / Metabolic health / Pediatric treatment / Weight management
Bariatric surgery is emerging as a safe, effective option for adolescents with severe obesity, improving weight, comorbidities, and quality of life, as clinical guidelines increasingly support earlier intervention alongside lifestyle and pharmacologic therapies.
Obesity Leaves Lasting DNA Methylation Memory in Immune Cells
April 27, 2026 / Obesity biology / Epigenetics / Immune system / Metabolic disease / Chronic inflammation
Obesity induces persistent epigenetic changes in immune cells, sustaining inflammation and metabolic dysfunction years after weight loss, helping explain ongoing risks for diabetes, cardiovascular disease, and cancer despite improved body weight.
Distinct Sex-Linked Cardiometabolic, Inflammatory Patterns Seen in Obesity
April 27, 2026 / Obesity differences / Cardiometabolic risk / Inflammation / Sex-based medicine / Metabolic health
Obesity exhibits distinct sex-specific cardiometabolic and inflammatory profiles, with men showing greater visceral and metabolic risk and women higher inflammatory markers, underscoring the need for tailored, sex-based approaches to obesity management.
Amazon One Medical introduces weight management program with upfront GLP-1 medication costs
April 21, 2026 / Obesity treatment / GLP-1 therapy / Primary care integration / Digital health / Weight management
Amazon One Medical launched an integrated GLP-1 weight management program combining primary care, pharmacy access, and virtual support to improve obesity treatment adherence, cost transparency, and management of related cardiometabolic conditions.
How bone marrow fat drives immune suppression and bone loss in obesity
April 24, 2026 / Bone health / Obesity / Immune suppression / PD-1 signaling / Metabolic disease
Bone marrow fat in obesity promotes immune suppression via PD-1/PD-L1 signaling, increasing osteoclast activity and bone loss, revealing a novel link between metabolism, immunity, and skeletal degradation.
Metabolic risk factors and clinical presentations of metabolic dysfunction-associated steatotic liver disease using data from the all of US research program
April 23, 2026 / Fatty liver disease / Metabolic syndrome / Cardiometabolic risk / Liver disease / Obesity
MASLD is strongly associated with obesity, diabetes, hypertension, and dyslipidemia, with risk profiles varying by ethnicity and age, and is linked to increased cardiovascular and liver complications, underscoring its role as a systemic metabolic disease.
GLP-1s May Reduce Asthma Exacerbations in Adults With Overweight and Obesity
April 22, 2026 / GLP-1 therapy / Asthma management / Obesity / Inflammation / Respiratory health
GLP-1 receptor agonists were associated with reduced asthma exacerbations in overweight and obese adults without diabetes, suggesting potential anti-inflammatory benefits beyond weight loss and metabolic control.
As heart, kidney and metabolic health worsen, cancer risk may rise, research indicates
April 27, 2026 / Cardiometabolic syndrome / Cancer risk / Chronic disease / CKM syndrome / Preventive health
Advanced cardiovascular-kidney-metabolic syndrome significantly increases cancer risk, with later disease stages linked to up to 30% higher incidence, highlighting shared pathophysiology and the need for integrated prevention and screening strategies.
Liver hormone regulates appetite and metabolism by targeting a specific group of hindbrain neurons
April 23, 2026 / Metabolic regulation / FGF21 hormone / Appetite control / Obesity research / Neuroendocrinology
FGF21, a liver-derived hormone, regulates appetite and energy expenditure by acting on hindbrain neurons, revealing a key neuro-metabolic pathway that could inform targeted therapies for obesity and metabolic disorders.
Prenatal stress may blunt metabolic benefits of exercise for offspring
April 22, 2025 / Prenatal health / Metabolic programming / Maternal stress / Brown fat / Developmental biology
Prenatal stress may impair the metabolic benefits of maternal exercise in offspring by altering corticosteroid signaling in brown fat, highlighting the role of maternal environment in shaping long-term metabolic health.
Fructose Metabolic Effects Study Says This Common Sweetener May Be Driving Obesity In Ways No One Realized
April 25, 2026 / Fructose metabolism / Obesity risk / Metabolic syndrome / Insulin resistance / Liver metabolism
Fructose functions as a metabolic signal promoting fat synthesis, insulin resistance, and energy imbalance, contributing to obesity and metabolic disease through distinct liver-driven pathways beyond caloric intake alone.
Cigarette exposure in the womb may amplify risk of metabolic disease in adulthood
Prenatal cigarette exposure may predispose offspring to worsened metabolic outcomes, with adult high-fat diets amplifying risks for obesity, dyslipidemia, and fatty liver disease through lasting effects on liver and adipose tissue.
A reasonably likely surrogate endpoint for metabolic dysfunction–associated steatohepatitis
April 28, 2026 / Liver disease / MASH / Biomarkers / Drug development / Noninvasive diagnostics
Current MASH drug development relies on invasive biopsy-based surrogate endpoints, limiting diagnosis and trial access; non-invasive biomarkers are needed to improve risk stratification, accelerate approvals, and expand patient access to care.
MASH Cirrhosis Trials Lack Consistent End Points
April 25, 2025 / MASH cirrhosis / Clinical trials / Drug development / Biomarkers / Liver disease
MASH cirrhosis trials lack standardized endpoints, limiting comparability and slowing drug development, highlighting the need for consensus frameworks incorporating clinical, biomarker, and patient-centered outcomes to improve evaluation of emerging therapies.